Practical management

1. Confirm and grade the hypertension
   • Repeat properly measured clinic BP and arrange home or ambulatory BP monitoring. Do not diagnose chronic hypertension from one reading.
   • Assess urgency: severe BP elevation, especially ≥180/120 mmHg, or symptoms/signs of acute end-organ injury such as chest pain, dyspnea, neurologic deficit, visual disturbance, severe headache, or acute kidney injury requires urgent emergency assessment.
   • Review other contributors: smoking/vaping, alcohol, NSAIDs, decongestants, stimulants, glucocorticoids, renal disease, sleep apnea, obesity, thyroid disease, diabetes, and family history.
2. Stop the ethinylestradiol-containing COC and replace it with physiologic menopausal hormone therapy
   • COCs can raise BP and carry more thrombotic and arterial risk in a woman who has hypertension.
   • For confirmed BP 140-159/90-99 mmHg, combined hormonal contraception is generally category 3, meaning risks usually outweigh benefits. At ≥160/100 mmHg, it is category 4 and should not be used. This is consistent with the CDC contraceptive eligibility criteria.
   • Since she has completed her family and does not need contraception, switch from the COC to:
     • Transdermal 17-beta estradiol 100 micrograms per 24 hours patch, changed as directed, or equivalent physiologic estradiol replacement, plus
     • progestogen for endometrial protection if her uterus is present.
   Transdermal estradiol is preferred here because it avoids hepatic first-pass effects and has less adverse effect on BP, coagulation factors, and triglycerides than oral ethinylestradiol. In a small POI crossover trial, transdermal estradiol plus progesterone produced lower BP than ethinylestradiol/norethisterone treatment. The international POI guideline supports physiologic estradiol-based therapy and reports this comparison.
3. Ensure progestogen protection If the uterus is intact, unopposed estrogen is unsafe.
   Reasonable options include:
   • Micronized progesterone 200 mg nightly for 12-14 days each month, producing expected withdrawal bleeding, or
   • Micronized progesterone 100 mg nightly continuously, often resulting in amenorrhea over time, or
   • a 52 mg levonorgestrel intrauterine system for endometrial protection, combined with transdermal estradiol. It also provides contraception, though this may not be needed.
   If she has had a total hysterectomy, use estrogen alone.
4. Treat hypertension independently
   • If BP remains elevated after withdrawing the COC, evaluate and treat it as hypertension according to local guidelines.
   • At age 36, especially if hypertension is marked, resistant, abrupt in onset, or accompanied by hypokalemia or renal impairment, assess for secondary causes such as renal disease, primary aldosteronism, thyroid disease, obstructive sleep apnea, and renovascular disease.
   • Choice of antihypertensive should consider comorbidities, renal function, potassium, and any chance of pregnancy. Family completion should not be assumed to mean pregnancy is impossible unless permanent contraception or infertility is established.
5. Assess cardiovascular and POI-related health
   • BMI/waist, smoking status, fasting lipid profile, HbA1c or glucose, creatinine/eGFR, urinalysis or urine albumin-creatinine ratio, electrolytes, and ECG when indicated.
   • Review diet, sodium intake, regular aerobic and resistance exercise, weight management, alcohol, and smoking cessation.
   • Confirm bone-health measures: adequate calcium intake, vitamin D if deficient, weight-bearing exercise, and DXA scanning if not already performed or if risk factors exist.

Follow-up

• Recheck BP within a few weeks of stopping the COC and initiating the replacement regimen, sooner if substantially elevated.
• Review adherence, bleeding pattern, vasomotor symptoms, migraine, VTE risk, and BP at follow-up.
• Continue POI hormone therapy to usual menopause age unless a genuine contraindication to estrogen develops. The ASRM POI guideline recommends ongoing hormone therapy in POI and at least annual BP, weight, smoking, and cardiovascular-risk review.